IMM-2510AXN-2510solid tumorsNSCLC
…reatment resulted in 70-95% tumor growth inhibition.Conclusions IMM-2510 is an anti-PD-L1xVEGF bispecific antibody designed to have immu…
1articles mentioning drugs
1drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: AXN-2510 ×
AXN-2510
This drug is selected. Its supporting articles are shown below.